Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.44 |
| ▸ | BAD | Q92934 | 1/20 | 0.44 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.43 |
| ▸ | PTAFR | P25105 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3943400 | 1.00 | CES2 (0.45) | CES2CES1BCL2L1BADTNFRSF1A | |
| SCHEMBL4033015 | 0.89 | CYP1A1 (0.52) | CES2CES1CYP1A2 | |
| SCHEMBL4033011 | 0.89 | CYP1A1 (0.52) | CES2CES1CYP1A2 | |
| SCHEMBL4033014 | 0.89 | CYP1A1 (0.52) | CES2CES1CYP1A2 | |
| SCHEMBL3940765 | 0.86 | PTGS2 (0.58) | — | |
| SCHEMBL3940758 | 0.86 | PTGS2 (0.58) | — | |
| SCHEMBL3943435 | 0.82 | HDAC3 (0.45) | CES2CES1TNFRSF1APTAFRCA1 | |
| SCHEMBL10399188 | 0.82 | HDAC3 (0.45) | CES2CES1TNFRSF1APTAFRCA1 | |
| SCHEMBL1232561 | 0.82 | HDAC3 (0.45) | CES2CES1TNFRSF1APTAFRCA1 | |
| SCHEMBL3945845 | 0.81 | ALOX15 (0.48) | CES2CES1PTAFRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2050734-A1 | PENTADIENAMIDE DERIVATIVE | Kyowa Hakko Kirin Co., Ltd. (JP) | 2009-04-22 | — | — | EP | disclosed |
| US-5332857-A | 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents | PFIZER INC. (US) | 1994-07-26 | — | — | US | disclosed |
| US-5151545-A | 3,5-DIHYDROXY-6,8-NONADIENOIC ACIDS AND DERIVATIVES AS HYPOCHOLESTEROLEMIC AGENTS | PFIZER INC. (US) | 1992-09-29 | — | — | US | disclosed |
| US-4975438-A | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0312269-A2 | 3,5-Dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents | PFIZER INC. (US) | 1989-04-19 | — | — | EP | disclosed |
| US-4788206-A | CARDIOVASCULAR DISORDERS, PLATELETS | HOFFMANN-LA ROCHE INC. (US) | 1988-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203667-A1 | PENTADIENAMIDE DERIVATIVES | PRMT1, REN, NGLY1 | CES2 3693/4885CES1 2445/4885BCL2L1 3700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.